Updated on 15 March 2013
The Cellradication processing technology selectively targets and kills undifferentiated cells in numerous cell lines, capable of forming teratomas. This process does not introduce any additional toxic agents while killing the undifferentiated cells, thus offering a safety advantage over competing technologies which may introduce cytotoxic agents that have to be removed before being administered to patients or do not kill the undifferentiated cells.
The Singapore-based start-up is developing bioprocessing tools based on this technology to develop and manufacture safe stem cell therapies.
The group is also developing additional technologies that have the potential to broaden the processes available within a regulated manufacturing environment to selectively yield the desired cell populations. VeriStem has generated extensive data detailing the precise mechanism of action, specificity of the technologies, destruction of only the undifferentiated (tumorigenic) cell populations and the conservation of these properties across various accepted bioprocessing formats.